NCT05911724

Association Between Inflammatory Biomarkers in CVD Patients on Empagliflozin.

Diagnostic and Prognostic Roles of Inflammatory Biomarkers in Coronary Heart Disease and Heart Failure Patients Treated With Empagliflozin.

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 180 (actual)
• Sponsor: Damanhour University · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The association of novel inflammatory biomarkers with cardiovascular diseases is still obscure. The present study aimed to investigate the relationship of various inflammatory biomarkers with the existence as well as the extent of heart failure (HF) and coronary artery disease (CAD), suggesting a link between inflammation and cardiovascular diseases and all-cause 30- and -90 day of hospital readmission. Methods: We enrolled a total of 120 patients with HF, asymptomatic CAD and 60 healthy controls (HC) without cardiovascular diseases.

Detailed description

* The present study aimed to investigate the relationship of various inflammatory biomarkers with the existence as well as the extent of heart failure (HF) and coronary artery disease (CAD), suggesting a link between inflammation and cardiovascular diseases and all-cause 30- and -90 day of hospital readmission in patients on empagliflozin 10 mg once daily for 6 months before the beginning of the study. * We enrolled a total of 60 patients with HF, 60 asymptomatic CAD patients and 60 healthy controls (HC) without cardiovascular diseases. Group I: 60 Healthy Subjects. Group II: 60 Patients with Stable Angina (asymptomatic CAD). Group III: 60 Patients with Heart Failure. * Clinical parameters, glycemic and lipid profile, vaspin, visfatin, high-sensitivity C-reactive protein, sortilin, homocysteine, troponin I, fetuin A and lipoprotein A levels were assayed. * Patients will be followed up to assess all-cause 30- and -90 day of hospital readmission.

Conditions

• Stable Angina
• Heart Failure

Interventions

Type	Name	Description
OTHER	Group I Healthy	Healthy Subjects
DRUG	CAD-Empagliflozin 10 mg once daily for 6 months before the beginning of the study	Group II: Stable Angina Patients
DRUG	HF-Empagliflozin 10 mg once daily for 6 months before the beginning of the study	Group III: Heart Failure Patients

Timeline

• Start date: 2023-03-01
• Primary completion: 2024-09-20
• Completion: 2024-09-30
• First posted: 2023-06-22
• Last updated: 2025-01-07

Locations

1 site across 1 country: Egypt